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Background: Positron emission tomography (PET) may be useful for defining the gross tumour volume for
radiation treatment planning and for response monitoring of non-small cell lung cancer (NSCLC) patients. The
purpose of this study was to compare tumour sizes obtained from CT- and various more commonly available
PET-based tumour delineation methods to pathology findings.
Methods: Retrospective non-respiratory gated whole body [18F]-fluoro-2-deoxy-D-glucose PET/CT studies from 19
NSCLC patients were used. Several (semi-)automatic PET-based tumour delineation methods and manual CT-based
delineation were used to assess the maximum tumour diameter.
Results: 50%, adaptive 41% threshold-based and contrast-oriented delineation methods showed good agreement
with pathology after removing two outliers (R2=0.82). An absolute SUV threshold of 2.5 also showed a good
agreement with pathology after the removal of 5 outliers (R2: 0.79), but showed a significant overestimation in the
maximum diameter (19.8 mm, p<0.05). Adaptive 50%, relative threshold level and gradient-based methods did not
show any outliers, provided only small, non-significant differences in maximum tumour diameter (<4.7 mm,
p>0.10), and showed fair correlation (R2>0.62) with pathology. Although adaptive 70% threshold-based methods
showed underestimation compared to pathology (36%), it provided the best precision (SD: 14%) together with
good correlation (R2=0.81). Good correlation between CT delineation and pathology was observed (R2=0.77).
However, CT delineation showed a significant overestimation compared with pathology (3.8 mm, p<0.05).
Conclusions: PET-based tumour delineation methods provided tumour sizes in agreement with pathology and
may therefore be useful to define the (metabolically most) active part of the tumour for radiotherapy and response
monitoring purposes.
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Positron emission tomography (PET) is a functional im-
aging modality that provides information about metabol-
ism, physiology and molecular biology of tumour tissue.
[18F]-fluoro-2-deoxy-D-glucose (FDG) is the most widely
used radiotracer that provides information on glucose
metabolism. There is an increasing interest in using
FDG PET not only to determine FDG uptake but also to* Correspondence: f.vvelden@vumc.nl
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reproduction in any medium, provided the origdetermine the location and extent of the metabolic ac-
tive part of the tumour. PET is being explored as a tool
for e.g. the definition of the gross tumour volume
(GTV), location of the metabolic active part of the
tumour for radiation oncology or monitoring response
during chemotherapy [1-3]. For radiation treatment
planning, the GTV is defined mainly on computed tom-
ography (CT), which provides anatomical image data.
CT imaging, however, has low contrast for soft tissue,
making it difficult to differentiate between tumour and
normal tissue due to their similar electron density
values. It is hypothesised that PET could improvehis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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ning [4]. Accurate GTV definition is vital in order to
generate a highly conformal radiation dose distribution,
thereby sparing surrounding normal tissue and allowing
a higher radiation dose to the most active part of the
tumour. In addition to improve the accuracy of GTV
definition, PET can indicate areas within the tumour that
are metabolically more active or malignant, which may
be used to define areas that need an additional radio-
therapy boost [5].
Another important application of FDG PET is its use
for the assessment of (early) treatment response and/or
as a prognostic factor. So far, these applications have
been mainly explored by studying FDG uptake quantita-
tively by means of standardised uptake values (SUV).
Nevertheless, other parameters, such as the metabolic
volume or total lesion glycolysis (product of SUV and
metabolic volume), may provide additional valuable in-
formation both as prognostic value as well as for treat-
ment response monitoring. Recently, metabolic tumour
volume or maximum metabolic tumour diameter have
been shown to be independent prognostic factors for
oesophageal cancer but only when accurate PET-based
tumour delineation methods are used [6]. Moreover, for
response monitoring studies it is important to know
whether a difference in SUV or metabolic tumour vol-
ume in successive scans represents a true response or
represents methodology-related variability. Therefore,
accurate and reproducible metabolic volume delineation
is important.
Several (semi-)automatic PET-based tumour delinea-
tion methods have been studied previously [7-12]. It is
generally accepted that pathology is the gold standard
and should be used for validation of tumour delineation
methods. However, only a limited number of (lung)
tumour studies [4,13-17] have been performed that com-
pare data obtained from (semi-)automatic PET-based
tumour delineation methods with pathological data.
Therefore, the primary purpose of this study was to
compare measured tumour sizes obtained from a broad
spectrum of (more commonly available) PET-based
tumour delineation methods to pathology findings. In
addition, CT-based tumour size assessments were com-
pared with pathology.
Methods
Patients, PET/CT and pathology
Included in this study were 19 consecutive patients (8
females and 11 males; weight 75±14 kg, range 42–100 kg)
with histological proven non-small cell lung cancer, who
had undergone a diagnostic whole body PET/CT scan
and underwent a surgical resection of their primary lung
tumour in the period from December 2003 to December
2004. All patients gave written informed consent priorto inclusion and the study was approved by the Medical
Ethics Review Board of the Maastricht University Medical
Center.
FDG data were acquired using a whole-body PET/CT
scanner (Biograph, Somatom Sensation 16; Siemens,
Erlangen, Germany). FDG was administered as an intra-
venous bolus (365±62 MBq). For each patient, plasma
glucose levels were measured (mean 5.7±2.1 mmolL-1,
range 4.1-12.0 mmolL-1) and all patients fasted for at
least 6 h before scanning. PET data were reconstructed
using ordered subsets expectation maximisation with 4
iterations and 18 subsets, followed by 5 mm full width at
half maximum (FWHM) Gaussian smoothing, resulting
in an image resolution of about 6.5 mm FWHM. All
PET images had a matrix size of 128×128×178, corre-
sponding to a pixel size of 5.31×5.31×5.00 mm3. CT data
had an image matrix size of 512×512×178, correspond-
ing to a pixel size of 0.98×0.98×5.00 mm3. CT data were
used to correct for tissue attenuation. More acquisition
and reconstruction details can be found elsewhere [4].
All patients underwent surgical resection of their pri-
mary tumour after approximately 47 d (range: 7 to 112 d).
Directly after surgical resection, the maximum diameter
of this tumour was measured by macroscopic exami-
nation in three dimensions using a calliper. Shrinkage
of the tumour, estimated to be around 10%, was not
considered as no preservation, fixation or inflation was
applied prior to the diameter measurements. The
obtained maximal diameters ranged from 1.5 to 7.0 cm
(mean: 4.0±1.8 cm). The primary tumours were located
in the superior (n=8), middle (n=1) or inferior (n=10)
lobe.
Data analysis
Maximum tumour diameters were measured for each
primary lung tumour volume. These tumour volumes
were obtained using six different types of PET-based
(semi-)automatic tumour delineation volume of interest
(VOI) methods:
1 Fixed threshold of 50% and 70% of maximum voxel
value (VOI50, VOI70) [18].
2 Adaptive threshold range of 41-70% of maximum
voxel value (VOIA41, VOIA50, VOIA70). Same as above,
except that it adapts the threshold relative to the
local average background [18].
3 Contrast-oriented method (VOISchaefer) [9]. This
method was recalibrated for the image characteristics
used.
4 Background-subtracted relative-threshold level (RTL)
method (VOIRTL). This method is an iterative method
based on a convolution of the point-spread function
that takes into account the differences between
various sphere sizes and the scanner resolution [7].
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method uses two steps before calculating the VOI.
First, this method calculates a gradient image on
which a ‘seed’ is placed in the tumour and another
one in the background. Next, a watershed (WT)
algorithm is used to grow the seeds in the gradient
basins, thereby creating boundaries on the gradient
edges. In our study, two different types of gradient
basins were used. The first approach, indicated by
GradWT1, assigns all voxels on the edge between the
tumour and the background to the tumour [10-12].
The second approach uses an upsampled image to
ensure less effects of sampling. In addition, voxels
that indicate an edge between the tumour and the
background are given to either the tumour or the
background depending on which region has a value
closest to the edge voxel value [12].
6 Absolute SUV (SUV2.5). Normalised (SUV) voxel
intensities at a chosen absolute threshold (2.5) are
used to delineate tumour [19].
More details on the methods used can be found in
[10-12]. In addition to PET-based tumour delineation, the
tumour was also delineated manually on the CT image by
an expert physician. Window and level settings were va-
ried according to the expertise by the expert physician.
The volume delineated on CT covered the whole primary
tumour.Figure 1 Mean differences between CT and PET derived
maximum tumour diameters and corresponding pathology
data. Percentage mean difference (A) or logarithmically transformed
mean difference (B) between maximum tumour diameters derived
from both manually delineated tumours on CT and several (semi-)
automatic PET-based delineation methods and corresponding data
from pathology. Error bars represent standard deviation.Statistical analyses
For the first analysis, the measured maximum tumour
diameters were compared with the maximum diameter
obtained from pathology. The maximum diameter was
obtained from the derived tumour volume by measuring
diameters in all possible directions, possibly including
spans of regions inside the tumour that are e.g. necrotic
or cystic. For each tumour delineation method, mean,
median, minimum and maximum values of maximum
diameter of the primary tumours were reported. In
addition, for each delineation method, correlation of
maximum diameter with corresponding pathology data
was determined.
As suggested by Wanet et al. [14], we also performed a
second analysis that uses a logarithmic transformation of
the data to reduce the magnitude of both skewness and
kurtosis of the volume distributions, so a nearly Gaussian
distribution of the data was obtained. For this analysis,
the difference in logarithmic transformed data was cal-
culated as ln diameterVOIð Þ  ln diameterpathology
 
, where
diameterVOI is the maximum tumour diameter of either
manual CT delineation or various PET-based tumour
volume delineation methods and diameterpathology is
the maximal pathological diameter. Correspondence inmaximal diameter for each tumour delineation method
was also evaluated by Bland-Altman plot analysis. P-
values were calculated using the two-tailed Wilcoxon
signed-rank test between maximal diameters obtained
from PET- or CT-based delineation and pathology. P-
values, which were lower than 0.05, were considered
statistically significant. Outliers were identified visually
as VOIs that showed an unrealistically large measured
tumour volume.
Results
During analyses VOI50, VOIA41, VOISchaefer and GradWT1
showed two outliers for which the generated VOI
resulted in unrealistically large volumes, as assessed
visually. In addition, SUV2.5 showed five outliers that
had an unrealistically large measured volume. Therefore,
all means and correlation analyses were corrected for
these outliers.
Figure 1 shows mean differences between CT and PET
derived maximum tumour diameters and corresponding
data obtained from pathology. Except for VOI70, VOIA70
and GradWT1 (−24.6, -35.9 and 24.4%, respectively),
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(−9.4 to 13%) than for manual CT delineation (15%).
VOI50, VOIA41 and VOISchaefer provided estimates of the
maximum diameter (−0.8, 3.0 and 3.9%, respectively) that
were closest to those obtained from pathology.
An identical trend can be seen in Table 1. The median
diameter (across tumours) obtained from VOI50 was
similar to that obtained from pathology (i.e. 0.6 mm dif-
ference; p=0.984). For CT-based delineation, corre-
sponding differences in median diameter were
significantly larger (3.8 mm difference; p=0.002). In
addition, a significant overestimation of median diameter
compared to pathology was found for SUV2.5 and
GradWT1 (19.8 and 13.8 mm difference, respectively;
p<0.05). Some other PET-based methods (i.e. VOIA41,
VOIA50, VOISchaefer, VOIRTL and GradWT2) provided
results that were not statistically different from path-
ology (p>0.10). However, median diameters obtained
from VOIA50, VOIRTL and GradWT2 were slightly smaller
(<4.7 mm differences) than those obtained from path-
ology. In contrast, only small differences in median
diameter obtained from VOIA41 and VOISchaefer (2.0 and
3.3 mm difference, respectively) were observed when
compared with pathology.
Table 2 shows the correlation of maximum diameters
obtained with various PET- and CT-based tumour delinea-
tion methods with pathology data. All PET-based methods
provided reasonable correlations (R2>0.62; slope 0.69-1.16),
except for GradWT1 (R2=0.43; slope 1.12). Although VOIA70
showed good correlation (R2=0.81), comparable withTable 1 Mean, median, minimum and maximum values of
maximum tumour diameter as obtained with different
methods
Method Maximum diameter (mm)
Mean Median Min Max p-valuea
Pathology 40.0 35.0 15.0 70.0 -
CT 48.1 38.8 17.3 137.0 0.002
PET
VOI50 39.4b 35.6 15.5 333.6 0.984
VOI70 30.9 24.1 11.3 71.4 <0.001
VOIA41 41.3b 37.0 15.5 330.6 0.623
VOIA50 37.2 30.3 12.5 92.0 0.104
VOIA70 26.6 22.5 10.6 62.3 <0.001
VOISchaefer 41.7b 38.3 15.5 333.6 0.568
VOIRTL 37.9 33.8 10.6 92.8 0.113
GradWT1 50.0b 48.8 32.5 83.2 0.003
GradWT2 36.2 32.3 19.5 79.0 0.156
SUV2.5 44.3b 54.8 12.5 643.4 0.009
aSignificance of the difference between tumour delineation method and
pathology.
bWithout outliers (2 for VOI50, VOIA41, VOISchaefer and GradWT1, 5 for SUV2.5).VOI50, VOIA41 and VOISchaefer, it resulted in an underesti-
mation of the maximum diameter (slope 0.69).
Figure 2 shows differences in maximum diameter derived
from various PET-based tumour delineation methods and
that obtained from pathological specimens. Also included is
the difference for manual CT delineation. For all patients,
most PET-based tumour delineation methods could mea-
sure the maximum tumour diameter with moderate accu-
racy. However, a bad correspondence between diameters
obtained with pathology and GradWT1 was found for small
tumours (≤2.5 cm diameter). When excluding these small
tumours, mean difference (15.7%) and correlation (R2=0.60,
slope 1.09) between diameters obtained with GradWT1 and
pathology moderately improved. Manual CT delineation
showed a large maximum diameter for two tumours with
heterogeneous FDG uptake (indicated by two arrows:
Figure 2A). Figure 3 shows VOIs obtained with various de-
lineation methods for the large primary tumour that is indi-
cated in other figures by a black arrow. For the tumour
indicated by the black arrow, only GradWT2 also showed a
large difference in diameter (−41.8%: Figure 2B). However,
for the tumour indicated by the grey arrow, three methods
(VOI50, VOIA41 and VOISchaefer) showed a large difference
in diameter (>485% difference). The same trend was seen
in Bland-Altman plots, as shown in Figure 4. For all meth-
ods, most data points were within the limits of agreement,
i.e. ±1.96×SD of the average), except for patients with large
heterogeneous tumours (indicated by the arrows) and
tumours located near high uptake regions (i.e. mediastinum
or heart). For GradWT1, however, one data point from a pa-
tient with a small primary tumour (1.8 cm diameter) was
not within the limits of agreement.Table 2 Linear regression data of maximum diameter
obtained using several delineation methods and
pathology
Delineation method R2 a Slopea
CT 0.77 1.25
PET
VOI50 b 0.82 1.00
VOI70 0.73 0.79
VOIA41 b 0.82 1.05
VOIA50 0.75 0.95
VOIA70 0.81 0.69
VOISchaefer b 0.83 1.06
VOIRTL 0.77 0.97
GradWT1 b 0.43 1.12
GradWT2 0.62 0.88
SUV2.5 b 0.79 1.16
aWith intercept set to 0.
bWithout outliers (2 for VOI50, VOIA41, VOISchaefer, and GradWT1, 5 for SUV2.5).
Figure 2 Differences in maximum diameter derived from
tumour delineation methods and that obtained from
pathology. Difference in maximum tumour diameter between
manual CT delineation (A) or various PET-based tumour volume
delineation methods (B-C) and pathological size as function of
pathological diameter. The arrows indicate two patients with
heterogeneous lung tumours. Note that two outliers each from
VOI50, VOIA41, VOISchaefer and GradWT1 fall outside the range of the
figure (i.e. >220%).
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Obtaining accurate (metabolic) tumour boundaries may
be important for treatment planning in radiotherapy and/
or for use as prognostic factor and/or to monitor response
during therapy, and may therefore have a direct impact on
clinical outcome.Tumour delineation methods are only suited for
radiotherapy planning purposes if they correspond
well with pathology. The present results indicate that
VOI50, VOIA41 and VOISchaefer show good agreement
with pathology after removing two outliers (R2: 0.82,
slope: 1.00-1.06, Figure 1). These outliers were located
closely to high uptake regions, e.g. mediastinum and
heart. Only those tumour delineation methods should
be selected for radiotherapy planning purposes if they
are able to distinguish between these adjacent normal
tissues and the tumour. VOIA50, VOIRTL and GradWT2
did not show any outliers, provided only small, non-
significant differences in maximum tumour diameter
(<4.7 mm, p>0.10), and showed fair correlation
(R2>0.62, slope 0.88-0.97) with pathology (Tables 1
and 2). These results correspond with those of pre-
vious studies [4,13], in which small differences in
maximum tumour diameter between an adaptive
threshold method and pathology were reported [13],
as well as good correlation between maximum dia-
meters obtained from a percentage threshold-based
method and pathology [4]. The latter study also
showed a reduction in inter-observer variability when
PET-based (semi-)automatic tumour delineation meth-
ods were used. GradWT1 showed only moderate agree-
ment with pathology (R2: 0.43) and overestimated the
maximum diameter. In addition, a poor agreement
obtained with pathology and GradWT1 was found for
small tumours (≤2.5 cm diameter). As the sizes of the
small tumours are less than three times the full-
width-at-half-maximum, the influence of partial vol-
ume effects may be relatively high, causing this poor
agreement with pathology. By applying modifications
to the algorithm (i.e. GradWT2), the method showed
more accurate tumour sizes (R2: 0.62). These findings
are in line with a previous study that compared
volumes derived with a gradient-based method to
pathology [14]. SUV2.5 showed a good agreement with
pathology after the removal of 5 outliers (R2: 0.79),
but showed a significant overestimation in the max-
imum diameter (19.8 mm, p<0.001). Due to the large
number of outliers and large overestimation in diam-
eter size, it is not recommended to use this method
for radiotherapy planning purposes.
Assessment of change in tumour size is important when
monitoring tumour response during therapy. Although
VOIA70 showed a large systematic underestimation (−36%)
of diameter, this method was the most precise (smallest SD
and coefficient of variation (COV, SDMean  100%) of 14 and
40%, respectively (Figure 1). For all other methods, SD and
COV ranged from 19 to 188% and from 77 to 448%, re-
spectively). In addition, good correlation (R2=0.81) between
maximum diameters obtained from this method and
Figure 3 Example volumes of interest (VOIs) obtained with various delineation methods for the large primary tumour. Example of axial
CT, fused PET/CT and PET images as well as VOIs obtained from CT-based and various PET-based delineation methods (VOIA41, VOIRTL, VOISchaefer,
GradWT1 and SUV2.5) for a lung tumour with heterogeneous FDG uptake. Note that the panes of fused PET/CT and PET images are interpolated to
match the CT. All other panes use the original image and voxel sizes.
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be a good method for response monitoring in which rela-
tive changes in (more active part of) metabolic volume are
considered.
Wu et al. [16] showed that CT-based delineation pro-
vided better correlation (R2=0.87) with pathology than
PET-based percentage threshold methods that did not
correct for background activity (R2=0.77). This is in con-
trast to the present study, where CT-based delineation
provided a slightly lower correlation of maximum diam-
eter with pathology than VOI50 (R2: 0.77 and 0.82, re-
spectively). In addition, CT-based delineation showed amoderate overestimation of maximum diameter com-
pared with pathology (slope: 1.25 and 1.00 for CT and
VOI50, respectively). Despite the good correlation, a
drawback of manual CT delineation is the requirement
of both a high resolution image (i.e. not a low dose CT)
and an experienced observer. Even if delineation is per-
formed by an experienced observer, manual CT delinea-
tion suffers from substantial interobserver variation [20].
In addition, accuracy of manual CT delineation was
shown to be dependent on the colour window settings
used [15,16]. Moreover, several conditions including
chronic obstructive lung disease (COPD), cavitation,
Figure 4 Bland-Altman analysis. Bland-Altman plots of the maximum tumour diameter obtained using CT- (A) and various PET-based (B-I)
delineation methods versus those derived from pathology. Dashed lines represent limits of agreement (±1.96×SD of the mean). Arrows indicate
two patients with large heterogeneous lung tumours. Note that two outliers from VOI50, VOIA41 and VOISchaefer fall outside the range of the figure
(i.e. >110 mm).
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which all occur frequently in lung cancer patients, ob-
scure the exact boundaries of the tumour on CT indu-
cing errors in measured tumour volume and/or diameter
size. In the present study, CT delineation has been
performed by only one expert physician. Although this
may weaken the strength of any correlation with pa-
thology, the results of this study were consistent with
the results from another study where manual CT de-
lineation was performed by two experienced observers
[17].
For the patient shown in Figure 3, large differences in
diameter were observed between CT- and PET-basedmethods. In this case, the primary tumour was located
close to another suspicious mass within the lymph node.
In addition, the primary tumour showed heterogeneous
FDG uptake, and both air-containing cavitation and fluid
level on the CT scan. Note that, for this typical example,
the measured tumour volume obtained using PET-based
delineation methods excluded this (non-metabolic) nec-
rotic and cystic centre that was included in manual CT
delineation. However, also note that this (non-metabolic)
necrotic and cystic centre was included in all maximum
diameter calculations. For this tumour, the maximum
diameter obtained from PET-based methods was closer
to that of pathology than for corresponding CT
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ences between anatomical (CT) and metabolic (PET)
volumes. As previously suggested [13], CT-based delin-
eation is unable to differentiate between high and low
activity regions, and the use of PET can assist in quanti-
fying and visualising heterogeneous tracer uptake across
the tumour and PET-based delineation may be useful to
define the most active part of the tumour.
Some factors might limit accurate delineation of
tumour volumes and corresponding maximum dia-
meters using the commonly available PET-based (semi-)
automatic tumour delineation described in this article.
First, primary lesions could be surrounded by high up-
take regions, e.g. from suspected locoregional metasta-
ses, heart and spine. Therefore, application of tumour
delineation methods might be more valid for peripheral
tumours and less valid for more centrally located
tumours, unless a (manually adjustable) bounding box
around the tumour is used to prevent delineation of sur-
rounding high uptake regions. Second, the metabolic
volume of tumours could show heterogeneous tracer up-
take that has been shown to have an impact on
threshold-based delineation methods [17]. Moreover,
tumours located in the thorax could be affected by re-
spiratory motion. However, a good correlation between
pathology and PET data is observed in the present study,
which might indicate that lung tumors might not be
strongly affected by these effects (at least not in this
study). Nevertheless, a slight mismatch between PET
and CT data can be observed in Figure 3. Fourth, it
should be noted that trends observed in the present
study may only be valid for primary lung tumours. For
other locations, the local background surrounding the
tumour is different, which could have an effect on the
performance of the tumour volume delineation methods
evaluated [11]. Finally, tumour delineation methods are
affected by several factors, such as scanner type, radio-
tracer, image noise and tumour characteristics [10,11].
So, additional evaluations with pathology, and/or opti-
misation of systems or tumour delineation methods may
be required for other PET/CT systems.
The present study showed some potential methodo-
logical limitations that might have influenced the results.
First, it should be noted that deformations could occur
between in-vivo CT imaging and ex-vivo pathology due
to the softness of lung tissue [21]. The method used in
the present study involved no inflation of the tissue after
resection nor other deformation compensation techni-
ques. All tumours were measured directly after surgery,
without using preservation. Inflation is required to find
the exact position of the lung tumour inside of the lung.
However, inflation is expected to influence mostly the
surrounding lung tissue, as the tumours imaged in this
study showed a relatively solid mass. The purpose of thecurrent study was not to determine the exact position,
but to measure the maximum diameter of the tumour.
In addition, the results of the present study are in line
with Siedschlag et al. [21] where inflation was used.
Therefore, deformations of the tumour after resection
are presumed to be negligible. However, ideally, a CT
scan of the excised tumour should have been made to
confirm that no deformations occurred. Second, no
pathological data on the volume of the primary tumour
was available. Therefore, only a comparison with max-
imum tumour diameter was made rather than with vol-
ume. Finally, it should be noted that in this study
pathological correlation is available only for resectable
lung tumours. However, the majority of patients that will
receive radiotherapy suffer from unresectable lung
tumours for which accurate tumour volume delineation
is critical for treatment. However, obtaining the true
volumes for this kind of tumour will remain a challenge
yet to be solved.
Conclusions
The maximum diameter derived from CT-based delinea-
tion was overestimated compared to pathology, especially
at large tumour diameters. PET-based tumour delineation
methods provided maximum diameter sizes in closer
agreement with pathology. The PET-based 50%, adaptive
41% threshold-based and contrast-oriented (Schaefer) me-
thods seem to be best suited for assessing tumour sizes
(of the metabolically most active part) of primary lung
tumours, as it provides the best correspondence with
pathology data. However, these methods could show a po-
tential difficulty when located close to high uptake regions.
Despite only a non-significant small underestimation com-
pared to pathology data, PET-based adaptive 50%, relative
threshold level and gradient-based methods could dis-
tinguish between the tumour and these adjacent high up-
take normal tissues, and are therefore recommended for
radiotherapy purposes. An adaptive 70% threshold-based
method may be best suited for response monitoring, as it
provides the best precision and best correlation with pa-
thology derived size without suffering from outliers.Competing interests
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